AUTHOR=Ni Jing , Cheng Xianzhong , Zhou Rui , Zhao Qian , Xu Xia , Guo Wenwen , Gu Hongyuan , Chen Chen , Chen Xiaoxiang 

TITLE=Adverse Events as a Potential Clinical Marker of Antitumor Efficacy in Ovarian Cancer Patients Treated With Poly ADP-Ribose Polymerase Inhibitor

JOURNAL=Frontiers in Oncology

VOLUME=Volume 11 - 2021

YEAR=2021

URL=https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2021.724620

DOI=10.3389/fonc.2021.724620

ISSN=2234-943X

ABSTRACT=Background: PARP inhibitor (PARPi) is an important progress in ovarian cancer treatment. The available evidence suggests that BRCAmt and homologous recombination deficiency (HRD) positive are effective biological markers for PARPi. We investigated the relationship between adverse events (AEs) and efficacy of PARPi in ovarian cancer patients.
Methods: Seventy-eight ovarian cancer patients underwent Olaparib and Niraparib were analyzed, including from July 2018 to July 2020. AEs were assessed by the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v5.0. Chi-square test or fisher exact tests was performed to observe the association between categorical variables. Logistic regression analysis was conducted to investigate the independent variables for disease control response (DCR). Progression-free survival (PFS) was compared between AEs variables by log-rank test. 
Results: Patients with AEs in the first one week had a higher DCR compared with after one week (86.11% versus 60.98%, p=0.013).Serious AEs (SAEs) had a significantly higher DCR (81.40% versus 60.60%, p=0.045). There were associations between anemia and DCR in both occurrence(79.63% versus 56.52%, p=0.037) and grade(100% versus 73.17%, p=0.048). The median PFS among patients with hematological toxicity was longer than with no-hematological toxicity patients (30 versus 20 weeks, p=0.047). Patients with hematological toxicity within four weeks had prolonged median PFS than who with hematological toxicity after four weeks (40 versus 22 weeks, p=0.003).
Conclusions: The early presence of AEs, and SAEs in hematological toxicity of PARPi were related to the antitumor efficacy, which might be a valid and easily measurable clinical marker in ovarian cancer patients.